Sign inJoin waitlistJoin the waitlist

Back to University of Washington Dermatopathology (Multidisciplinary)

Paul Nghiem

Dermatopathology Fellowship · University of Washington School of Medicine

Credentials: · ·

History

Dermatopathology
University of Washington School of Medicine
2026–Present
Harvard University Fellowship
2001–2002
Dermatology
Mass General Brigham
1995–1998
Massachusetts General Hospital
1995–1998
Preliminary or Transitional Year
1994–1995
Stanford University School of Medicine
1990–1994

Research

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
New England Journal of Medicine · 2016 · First of 31 authors · 992 citations
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
The Lancet Oncology · 2016 · Last of 18 authors · 955 citations
Spatial transcriptomics at subspot resolution with BayesSpace
Nature Biotechnology · 2021 · 726 citations

Shailender Bhatia
58 papers
KP
Kelly Paulson
46 papers · 20 as a resident
JI
Jayasri Iyer
33 papers · 14 as a resident
Song Park
26 papers
David Koelle
22 papers
UP
Upendra Parvathaneni
22 papers
Tomoko Akaike
21 papers · 5 as a fellow
KN
Kishwer Nehal
16 papers
Ashok Shaha
15 papers
Christopher Bichakjian
15 papers
Murad Alam
15 papers · 1 as a fellow
Natalie Miller
14 papers · 8 as a resident

Grants

Immunobiology and Immune Therapy for Merkel Cell Carcinoma
National Cancer Institute · P01
Contact PI · $19.8M · University of Washington
2019–2030
Mechanisms of UV-Induced DNA Damage Responses and Carcinogenesis in Skin
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
Contact PI · $2M · University of Washington
2015–2022
Pathogenetic and Prognostic Studies for Improved Therapy of Merkel Cell Carcinoma
National Cancer Institute · K24
Contact PI · $1.8M · University of Washington
2009–2019
Viral Oncoprotein Targeted Immune Therapy for Merkel Cell Carcinoma
National Cancer Institute · R01
Contact PI · $2.6M · University of Washington
2013–2019

Clinical trials

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2014–2021